KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) EPS (Basic) (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed EPS (Basic) for 16 consecutive years, with -$1.17 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Basic) fell 208.33% to -$1.17 in Q4 2025 year-over-year; TTM through Dec 2025 was $2.64, a 24.57% decrease, with the full-year FY2025 number at $2.64, down 24.57% from a year prior.
  • EPS (Basic) was -$1.17 for Q4 2025 at Halozyme Therapeutics, down from $1.49 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $1.53 in Q3 2021 to a low of -$1.17 in Q4 2025.
  • A 5-year average of $0.63 and a median of $0.62 in 2023 define the central range for EPS (Basic).
  • Peak YoY movement for EPS (Basic): surged 600.0% in 2021, then plummeted 208.33% in 2025.
  • Halozyme Therapeutics' EPS (Basic) stood at $0.49 in 2021, then decreased by 12.24% to $0.43 in 2022, then surged by 51.16% to $0.65 in 2023, then surged by 66.15% to $1.08 in 2024, then tumbled by 208.33% to -$1.17 in 2025.
  • Per Business Quant, the three most recent readings for HALO's EPS (Basic) are -$1.17 (Q4 2025), $1.49 (Q3 2025), and $1.36 (Q2 2025).